Pharma BD Deal Intelligence
A $3.1 billion co-development collaboration that paired BMS's development muscle with Eisai's MORAb-202, a folate receptor alpha-targeting antibody-drug conjugate for advanced solid tumors. No milestone or upfront breakdown was disclosed, and no completed outcome assessment exists yet to confirm whether the partnership delivered.
Eisai and BMS end their $3.1 billion ADC deal, but Eisai announced it will continue independent development of MORAb-202 as a folate receptor alpha-targeted…
Phase 2 randomized NSCLC adenocarcinoma study of MORAb-202 (farletuzumab ecteribulin) TERMINATED; whyStopped: 'Business objectives have changed.' Last update…
Phase 2 open-label randomized study of farletuzumab ecteribulin vs investigator's choice chemotherapy in platinum-resistant HGS…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS and Eisai entered a global co-development collaboration for MORAb-202, a folate receptor alpha-targeting ADC for advanced solid tumors.
FRalpha-positive platinum-resistant ovarian cancer is a differentiated niche already claimed by a first-in-class ADC. Anti-FRalpha ADCs (direct MOA): AbbVie/ImmunoGen's Elahere (mirvetuximab soravtansine-gynx) is FDA-approved for FRalpha-high platinum-resistant ovarian cancer (accelerated 2022, full 2024 via MIRASOL) with approximately $479M 2024 sales and $100M+ quarterly run-rate; farletuzumab ecteribulin (MORAb-202) is the direct Phase 2 follower with an eribulin (microtubule) payload vs. Elahere's DM4 (maytansinoid). PARP inhibitors (maintenance standard): AstraZeneca/Merck's Lynparza (olaparib, $3.5B+ 2024 sales), GSK's Zejula (niraparib, ~$570M 2024), and Clovis/pharma&'s Rubraca (rucaparib) maintain 1L/2L maintenance in BRCA/HRD+. Anti-VEGF + chemo: Roche's Avastin (bevacizumab) and biosimilars dominate the bevacizumab-combo segment in platinum-sensitive and resistant disease. Chemotherapy: liposomal doxorubicin (Doxil), topotecan, weekly paclitaxel remain SOC backbone. Anti-PD-1: Keytruda (pembrolizumab) has limited ovarian activity. Other FRalpha strategies: Sutro's luveltamab tazevibulin (STRO-002) Phase 2/3 REFRaME. For a commercial lead, MORAb-202's commercial window in ovarian is tight — Elahere's MIRASOL OS benefit and first-mover label leave MORAb-202 dependent on either superior efficacy at lower FRalpha thresholds or better safety (ocular toxicity a known Elahere liability).
MORAb-202 targets advanced/recurrent endometrial cancer where FRalpha expression is high and the 1L/2L treatment paradigm has shifted to chemo-IO combinations. Anti-FRalpha ADCs (direct MOA): AbbVie/ImmunoGen's Elahere (mirvetuximab soravtansine) is the only approved FRalpha ADC, labeled in platinum-resistant ovarian cancer and generating approximately $479M 2024 sales with endometrial Phase 2 data emerging; farletuzumab ecteribulin (MORAb-202) is the direct ADC competitor still in Phase 2. Anti-PD-1 + tyrosine kinase inhibitor combos (current 1L/2L SOC): Merck/Eisai's Keytruda + Lenvima (pembrolizumab + lenvatinib) is FDA-approved in pMMR advanced EC post-platinum, with Keytruda generating $29.5B in 2024 and Lenvima approximately $1.3B in combined global sales. Anti-PD-1 monotherapy (dMMR/MSI-H): Merck's Keytruda (pembrolizumab) and GSK's Jemperli (dostarlimab, RUBY/NRG-GY018 1L chemo combo approved) define the dMMR segment; Jemperli 2024 sales reached approximately $622M. Chemotherapy: carboplatin/paclitaxel remains backbone. HER2-directed ADC: AstraZeneca/Daiichi's Enhertu (trastuzumab deruxtecan, pan-tumor HER2 accelerated approval) has endometrial data in HER2+ subset. For a commercial lead, MORAb-202's threat depends on FRalpha expression frequency in EC and whether its eribulin payload differentiates from Elahere's DM4; Keytruda+Lenvima's entrenched 1L position leaves only 2L/3L biomarker-selected opportunity.
BMS and Eisai entered global co-development for MORAb-202, a FRa-targeting ADC for solid tumors.
BMS terminated collaboration due to portfolio prioritization. Eisai regained all rights, accelerating solo development.
Post-termination of the BMS partnership, the Phase 2 NSCLC adenocarcinoma study (NCT05577715) was terminated ('business objectives have changed'), narrowing Eisai's solo program toward gynecologic indications.
BMS exited for strategic reasons. Eisai continues Phase III solo. Not a clinical failure but a strategic reallocation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Eisai Co., Ltd. (this deal) | 2021 | $3.1B | 45 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2021 deals · Bristol-Myers Squibb Company deals · Oncology deals